Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.34 |
| ▸ | LPL | P06858 | 10/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113584 | 0.80 | LPL (0.41) | SNCALIPGLPLIDO1TDO2 | |
| SCHEMBL23529729 | 0.80 | SNCA (0.38) | SNCALIPGLPLIDO1TDO2 | |
| SCHEMBL30928610 | 0.79 | IDO1 (0.39) | SNCALIPGLPLIDO1TDO2 | |
| SCHEMBL23291683 | 0.79 | EGFR (0.34) | IRAK4 | |
| SCHEMBL31413889 | 0.79 | — | — | |
| SCHEMBL23546525 | 0.79 | SNCA (0.36) | SNCALIPGLPLIDO1TDO2 | |
| SCHEMBL31394882 | 0.78 | LPL (0.43) | SNCALIPGLPLIDO1TDO2 | |
| SCHEMBL17426055 | 0.78 | KLKB1 (0.37) | — | |
| SCHEMBL26093683 | 0.77 | LIPG (0.39) | SNCALIPGLPLFFAR1CA1 | |
| SCHEMBL23633173 | 0.77 | LPL (0.36) | SNCALIPGLPLIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411431-A1 | Novel compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220411431-A1 | Novel compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-11466011-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| EP-3313833-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-20200339586-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
| US-20200339586-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
| US-10759804-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-10759804-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20180370974-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9416126-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416126-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160009696-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009696-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2014134772-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759804-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | NMT1, NMT2, GNMT | SNCA 4458/4885LIPG 441/4885LPL 1350/4885 |
| US-20220411431-A1 | Novel compounds and their use in therapy | NMT1, NMT2, FNTA | SNCA 4718/4885LIPG 451/4885LPL 1723/4885 |
| US-11466011-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | NMT1, NMT2, GNMT | SNCA 4458/4885LIPG 441/4885LPL 1350/4885 |
| US-20160009696-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | SNCA 147/4885LIPG 1941/4885LPL 836/4885 |
| US-20180370974-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | NMT1, NMT2, GNMT | SNCA 4458/4885LIPG 441/4885LPL 1350/4885 |
| US-20200339586-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | NMT1, NMT2, GNMT | SNCA 4458/4885LIPG 441/4885LPL 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.